Ethna McFerran
Overview
Explore the profile of Ethna McFerran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adair O, Lamrock F, OMahony J, Lawler M, McFerran E
Value Health
. 2025 Jan;
PMID: 39880192
Objectives: Cost-effectiveness analysis (CEA) is an accepted approach to evaluate cancer screening programs. CEA estimates partially depend on modeling methods and assumptions used. Understanding common practice when modeling cancer relies...
2.
Shah R, Hanna N, Loo C, David M, Mafra A, Fink H, et al.
Nat Cancer
. 2025 Jan;
6(1):194-204.
PMID: 39747650
The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on...
3.
Shah R, Loo C, Hanna N, Hughes S, Mafra A, Fink H, et al.
J Cancer Policy
. 2024 Jun;
41:100486.
PMID: 38830535
During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care...
4.
McFerran E, Donaldson S, Dolan O, Lawler M
J Cancer Policy
. 2024 Feb;
39:100468.
PMID: 38311308
Background: Skin cancer is a prevalent cancer in the UK. Its rising incidence and mortality rates are expected to result in substantial financial implications, particularly on diagnostic and treatment services...
5.
Pokharel R, Lin Y, McFerran E, OMahony J
Appl Health Econ Health Policy
. 2023 Jun;
21(5):701-717.
PMID: 37380865
Objective: To assess the range of strategies analysed in European cost-effectiveness analyses (CEAs) of colorectal cancer (CRC) screening with respect to the screening intervals, age ranges and test cut-offs used...
6.
McFerran E, Cairnduff V, Elder R, Gavin A, Lawler M
Support Care Cancer
. 2023 Mar;
31(3):201.
PMID: 36869930
Objectives: Cancer is a leading cause of death. This paper examines the utilisation of unscheduled emergency end-of-life healthcare and estimates expenditure in this domain. We explore care patterns and quantify...
7.
Adair O, McFerran E, Owen T, McKee C, Lamrock F, Lawler M
Syst Rev
. 2023 Jan;
12(1):14.
PMID: 36707908
Background: Colorectal cancer (CRC) is becoming an increasing health problem worldwide. However, with the help of screening, early diagnosis can reduce incidence and mortality rates. To elevate the economic burden...
8.
Henderson R, French D, McFerran E, Adams R, Wasan H, Glynne-Jones R, et al.
J Cancer Policy
. 2022 Jun;
33:100342.
PMID: 35718327
Background: In 2014, the COIN-B clinical trial demonstrated that intermittent cetuximab (IC) was a safe alternative to continuous cetuximab (CC), with less cytotoxic chemotherapy, in first-line treatment for KRAS wild-type...
9.
McFerran E, OMahony J, Naber S, Sharp L, Zauber A, Lansdorp-Vogelaar I, et al.
MDM Policy Pract
. 2022 May;
7(1):23814683221097064.
PMID: 35573867
Colorectal cancer (CRC) prevention programs using fecal immunochemical testing (FIT) in screening rely on colonoscopy for secondary and surveillance testing. Colonoscopy capacity is an important constraint. Some European programs lack...
10.
Henderson R, French D, Maughan T, Adams R, Allemani C, Minicozzi P, et al.
Lancet Gastroenterol Hepatol
. 2021 Jul;
6(9):709-722.
PMID: 34329626
Background: Colorectal cancer is one of the leading causes of cancer morbidity and mortality in Europe. We aimed to ascertain the economic burden of colorectal cancer across Europe using a...